Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals (myBIOM)

3 de novembro de 2026 atualizado por: Chr Hansen - part of Novonesis

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study

The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.

The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

90

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Blackpool
      • Cork, Blackpool, Irlanda, T23 R50R

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

45 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Be able to give informed consent.
  2. Be between 45 to 70 years of age (inclusive).
  3. BMI <40.0 kg/m²
  4. Willing to maintain current level of physical activity and diet during the participation in the study.
  5. Experience ≤4 bowel movements per week within the month prior to screening
  6. Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening.
  7. Willing to consume the study product daily for the duration of the study.
  8. Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).

Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period

Exclusion Criteria:

  1. Has a history of drug and/or alcohol abuse.

  2. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  3. Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.

  4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:

    1. diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)
    2. GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.
    3. history of CVD
    4. uncontrolled hypertension
  5. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:

    1. systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1
    2. OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1

10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:

a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.

9. Planned major changes in lifestyle [i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling] during the duration of the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Synbiotic

Synbiotic dietary supplement

Synbiotic

- Given daily for 56 days

Comparador de Placebo: Placebo

Identical looking placebo consisting of maltodextrin

Placebo

- Given daily for 56 days

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Bifidobacterium abundance
Prazo: From baseline to end of intervention at 8 weeks

Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing.

From baseline to end of intervention at 8 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Stool frequency
Prazo: From baseline to end of intervention at 8 weeks

Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable.

From baseline to end of intervention at 8 weeks
Fecal acetate
Prazo: From baseline to end of intervention at 8 weeks.

Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal propionate
Prazo: From baseline to end of intervention at 8 weeks.

Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal butyrate
Prazo: From baseline to end of intervention at 8 weeks

Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Zonulin
Prazo: From baseline to end of intervention at 8 weeks

Change in serum zonulin from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Lipopolysaccharide binding protein (LPS-BP)
Prazo: From baseline to end of intervention at 8 weeks

Change in plasma LPS-BP from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Interleukin 6 (IL-6)
Prazo: From baseline to end of intervention at 8 weeks

Change in serum IL-6 from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
High-sensitivity C-Reactive Protein (hsCRP)
Prazo: From baseline to end of intervention at 8 weeks

Change in serum hsCRP from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Fecal Short-Chain Fatty Acids (SCFA)
Prazo: From baseline to end of intervention at 8 weeks

Change in composite measurement of fecal SCFAs panel with targeted metabolomics (GC-MSMS) from baseline to 8 weeks. Total composite is defined as: acetate + propionate + butyrate.

From baseline to end of intervention at 8 weeks
Stool consistency
Prazo: From baseline to end of intervention at 8 weeks

Change in mean stool consistency assessed daily from 2 weeks prior to baseline to daily 2 weeks prior to end-of intervention. Stool consistency will be assessed by Bristol stool chart scale rated Type 1 (separate hard lumps) to Type 7 (watery, no solid pieces). An increase in stool consistency is desirable.

From baseline to end of intervention at 8 weeks
Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score
Prazo: From baseline to end of intervention at 8 weeks

Change in GSRS-IBS composite score from baseline to end-of-intervention visit. The GSRS-IBS questionnaire includes 13 items that measure the severity of IBS symptoms in five clusters (pain, bloating, constipation, diarrhea and early satiety) during the last seven days. A decrease is desirable.

From baseline to end of intervention at 8 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Recovery of probiotic strains
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Recovery and colonization of strains by strain specific qPCR of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Total relative abundance of Bifidobacterium
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.

Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
Microbiome composition and taxonomic profiles
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Microbiome functional profiling
Prazo: Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples

Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Plasma Metabolomics
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in blood metabolome as assessed by untargeted and targeted metabolomics from plasma samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Fecal metabolomics
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in fecal metabolome as assessed by untargeted and targeted metabolomics from fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Bacterial HMO utilization genes
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Abundance development over time of HMO degradation and modification genes such as Glycosyl hydrolases, encoded by probiotic supplements and endogenous gut species

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
HMO concentration in blood and feces
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in HMO in plasma and fecal samples after 3 and 8 weeks of supplementation

Baseline, 3 weeks and end of intervention at 8 weeks
Fecal pH
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in pH assessed using a pH meter in fecal samples

Baseline, 3 weeks and end of intervention at 8 weeks
Inflammatory Biomarkers
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in inflammatory biomarkers measured in serum

Baseline, 3 weeks and end of intervention at 8 weeks
Cardiometabolic Biomarkers
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in cardiometabolic biomarkers

Baseline, 3 weeks and end of intervention at 8 weeks
Cognitive function measured by the Trails Making Test (Parts A & B)
Prazo: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using Trail Making Test (Parts A & B)

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Stroop Colour and Word Test
Prazo: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Stroop Colour and Word Test

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Symbol Digit Modalities Test (SDMT)
Prazo: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Symbol Digit Modalities Test (SDMT)

Baseline and end of intervention at 8 weeks
Health-related Quality of Life
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in health-related quality of life assessed by Short Form-36 (RAND SF-36)

Baseline, 3 weeks and end of intervention at 8 weeks
Gastrointestinal Symptoms Measured by the GSRS-IBS Total Score
Prazo: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gastrointestinal symptoms by assessing the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). The outcome reflects the total composite score. A decrease is desirable.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
GSRS-IBS Pain Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.

Change in the gastrointestinal symptom pain assessed using GSRS-IBS subscale for Pain. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
GSRS-IBS Bloating Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom bloating assessed using GSRS-IBS subscale for bloating. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Constipation Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom constipation assessed using GSRS-IBS subscale for constipation. A decrease is desirable

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Diarrhea Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom Diarrhea assessed using GSRS-IBS subscale for Diarrhea. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Early Satiety Subscale
Prazo: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom early satiety assessed using GSRS-IBS subscale for early satiety.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
Protein Composite Score
Prazo: Baseline, 3 weeks and end of intervention at 8 weeks

Change in protein composite score measured using OLINK Reveal panel

Baseline, 3 weeks and end of intervention at 8 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Martin Buckley, Professor, Atlantia Clinical Trials Ltd

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de março de 2026

Conclusão Primária (Estimado)

1 de outubro de 2027

Conclusão do estudo (Estimado)

1 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

24 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de março de 2026

Primeira postagem (Real)

6 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • HHB-GI-2406
  • ECM4(i)11/12/2025 (Outro identificador: Clinical Research Ethics Committee of the Cork Teaching Hospitals)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever